Huya Bioscience will support Organon in the sourcing and development Chinese pharmaceutical or biopharmaceutical compounds in three specific therapeutic areas. As part of this collaboration, Organon has acquired an equity interest in Huya.
David Nicholson, executive vp R&D at Organon points out that this collaboration agreement “is consistent with our research strategy to forge closer links with China's highly skilled and motivated scientists and significantly expands our own ongoing biotech research programs and capabilities.”
This transaction follows other research collaborations that Organon has signed with Chinese biotech companies, such as Shanghai Genomics and HD Biosciences.